A Phase I Open Label Pilot Study to Evaluate the Safety, Efficacy and Tolerability of Anginera for Adults With Left Ventricular Dysfunction AND Reversible Myocardial Ischemia Undergoing CABG Surgery
Latest Information Update: 20 Oct 2023
At a glance
- Drugs Fibroblast cell therapy (Primary)
- Indications Left ventricular dysfunction; Myocardial ischaemia
- Focus Adverse reactions
- Sponsors Theregen
- 27 May 2014 New trial record